US 12,433,945 B2
Peanut oral immunotherapy with maintenance dose
Daniel Adelman, Brisbane, CA (US)
Assigned to Société Des Produits Nestlé S.A., Vevey (CH)
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH)
Filed on Aug. 15, 2019, as Appl. No. 16/542,198.
Claims priority of provisional application 62/809,236, filed on Feb. 22, 2019.
Claims priority of provisional application 62/765,123, filed on Aug. 16, 2018.
Prior Publication US 2020/0054738 A1, Feb. 20, 2020
Int. Cl. A61K 39/35 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61P 37/08 (2006.01)
CPC A61K 39/35 (2013.01) [A61K 9/0053 (2013.01); A61P 37/08 (2018.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01)] 14 Claims
 
1. A method of treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase, the method comprising:
(a) administering to the subject the up-dosing phase;
(b) administering to the subject a maintenance phase dose for more than 24 weeks;
(c) testing the subject for a highest tolerated peanut protein dose by an oral food challenge;
(d) selecting a subject for additional maintenance phase dosing based on the subject tolerating a maximum dose of less than 1,000 mg peanut protein; and
(e) continuing to administer to the selected subject the maintenance phase dose; wherein the maintenance phase dose comprises 300 mg of peanut protein.